ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2022
Detection of 10 cases of ceftriaxone-resistant
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.The Journal of infectious diseases · 2025Pooled it
- Aerocavin Is an Antibiotic with Potent and Specific Anti-Neisserial Activity.ACS infectious diseases · 2026Article
- Article
- Rapid detection of ceftriaxone-resistantMicrobiology spectrum · 2026Article
- Antimicrobial resistance crisis in STIs: Gonorrhea andNew microbes and new infections · 2026Review
- Stepwise evolution and clonal enrichment of gepotidacin resistance inAntimicrobial agents and chemotherapy · 2026Article
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- In Vitro Activity of Zoliflodacin AgainstAntibiotics (Basel, Switzerland) · 2026Article
- Detection of non-travel-associated, ceftriaxone non-susceptibleCanada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- Emergence, evolution and temporal spread of ceftriaxone-resistantEmerging microbes & infections · 2025Article
- Investigation of ceftriaxone-resistantSexually transmitted infections · 2025Article
- Estimating the undetected burden and the likelihood of strain persistence of drug-resistant Neisseria gonorrhoeae.American journal of epidemiology · 2025Article
- High Prevalence of Ceftriaxone-Resistant Neisseria gonorrhoeae in Hanoi, Vietnam, 2023-2024.The Journal of infectious diseases · 2025Article
- CRISPRi-mediated repression of threeJournal of bacteriology · 2025Article
- Oxydifficidin, a potenteLife · 2025Article
- Increase inSexually transmitted infections · 2025Article
- Rationale and Ethical Assessment of an Oropharyngeal Gonorrhea Controlled Human Infection Model.The Journal of infectious diseases · 2025Article
- Immunogenic evaluation of LptD + LtgC as a bivalent vaccine candidate against Neisseria gonorrhoeae.Journal of translational medicine · 2025Article
- Antimicrobial Resistance in Curable Sexually Transmitted Infections.Current HIV/AIDS reports · 2025Review
- Clinical Studies Are Needed to Determine the Efficacy of Ceftriaxone and Other Interventions in Addressing Resistant Neisseria gonorrhoeae Infection.Sexually transmitted diseases · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Between December 2021 and June 2022, 10 cases of ceftriaxone-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.